Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7699687 | 0.86 | CHRNA7 (0.50) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL7047117 | 0.82 | CHRNA7 (0.54) | CHRNA7HTR3A | |
| SCHEMBL7118206 | 0.81 | CHRNA7 (0.53) | CHRNA7HTR3A | |
| SCHEMBL7708591 | 0.80 | CHRNA7 (0.51) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL2230468 | 0.79 | CHRNA7 (0.54) | CHRNA7 | |
| SCHEMBL2230461 | 0.79 | CHRNA7 (0.54) | CHRNA7 | |
| SCHEMBL2228215 | 0.79 | CHRNA7 (0.64) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL2228214 | 0.79 | CHRNA7 (0.64) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL7281094 | 0.79 | CHRNA7 (0.64) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL7156786 | 0.77 | CHRNA7 (0.61) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049225-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049225-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | UGT1A1, NAT1, SLC10A1 | CHRNA7 365/4885HTR3A 995/4885KCNH2 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.